Patent · US Active

Progesterone antagonist and selective progesterone modulator in the treatment of excessive uterine bleeding

US8569274B2 · kind B2 · utility

8Cited by

2References

14Claims

0Family size

Assignee

PregLem SA · CH

Inventors

Bartholomeus C.J.M. Fauser · Rotterdam, NL
Ernest Loumaye · Cologny, CH

Key dates

Filing date	Apr 18, 2008
Grant date	Oct 29, 2013
Priority date	—
Expiry date	Jul 13, 2030

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P15/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Progesterone antagonists and SPRM are useful to prepare a medication for the treatment or the prophylaxis of excessive uterine bleeding in women with spontaneous or iatrogenic coagulation disorders such as thrombopenia, coagulation factor deficiency or anti-coagulant therapy. Treatment will last from 1 day to 180 days.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.